Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome
Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome
复制标题
DOI：
10.1210/jc.2004-0176
复制
发表时间：
2005-02-01
影响因子：
5.8
通讯作者：
Atkin, SL
中科院分区：
文献类型：
--
作者：
Jayagopal, V;Kilpatrick, ES;Atkin, SL
本研究的目的是评估和比较奥利司他与二甲双胍治疗对多囊卵巢综合征 (PCOS) 患者激素和生化特征的影响。21 名患有 PCOS 的白人女性 [平均 (+/-SEM) 年龄 27 +/- 0.9 岁，体重指数 36.7 +/- 3.3 kg/m(2)] 参与了这项前瞻性、随机、 开放标签研究。所有受试者均接受为期 8 周的饮食调整磨合期，然后随机接受二甲双胍（500 毫克，每日 3 次）或奥利司他（120 毫克，每日 3 次）治疗，为期 3 个月。在筛选、随机分组和完成时采集体重、血压和空腹血样。使用稳态评估模型（HOMA）-IR 方法计算胰岛素抵抗（IR）[HOMA-IR =（胰岛素 X 葡萄糖）/22.5]。结果表示为平均值 +/- SEM。与基线相比，奥利司他治疗 [93.5 +/- 11.5 ng/dl (3.24 +/- 0.4 nmol/L) vs. 114.5 +/- 11.5 ng/dl (3.97 +/- 0.4 nmol/L)，P = 0.039] 和二甲双胍 [97.2 +/- 11.5 ng/dl (3.37) +/- 0.4 纳摩尔/升） vs. 120.0 +/- 8.7 ng/dl (4.16 +/- 0.3 nmol/L), P = 0.048] 导致总睾酮显着降低。奥利司他治疗使体重减轻了 4.69%（99.0 +/- 6.0 vs. 94.6 +/- 6.1 kg，P = 0.002），并且这种减轻比二甲双胍产生的减轻更为显着（4.69 vs. 1.02%，P = 0.006）。在空腹胰岛素、HOMA-IR、性激素结合球蛋白或任何研究的脂质参数的任一治疗组后，均未观察到显着降低。在这项研究中，奥利司他使体重和总睾酮显着降低。总睾酮的减少与二甲双胍治疗后的情况相似。因此，奥利司他可能被证明是治疗多囊卵巢综合症的有用辅助药物。
The objective of this study was to evaluate and compare the effect of treatment with orlistat vs. metformin on the hormonal and biochemical features of patients with polycystic ovarian syndrome (PCOS).Twenty-one Caucasian women with PCOS [mean (+/-SEM) age 27 +/- 0.9 yr and body mass index 36.7 +/- 3.3 kg/m(2)] participated in this prospective, randomized, open-labeled study. All subjects had an 8-wk run-in period of dietary modification and then randomized to receive either metformin (500 mg three times daily) or orlistat (120 mg three times daily) for 3 months. Weight, blood pressure, and fasting blood samples were taken at screening, randomization, and on completion. Insulin resistance (IR) was calculated using the homeostasis model of assessment (HOMA)-IR method [HOMA-IR = (insulin X glucose)/22.5].The results are expressed as mean +/- SEM. When compared with baseline, treatment with both orlistat [93.5 +/- 11.5 ng/dl (3.24 +/- 0.4 nmol/liter) vs. 114.5 +/- 11.5 ng/dl (3.97 +/- 0.4 nmol/ liter), P = 0.039] and metformin [97.2 +/- 11.5 ng/dl (3.37 +/- 0.4 nmol/liter) vs. 120.0 +/- 8.7 ng/dl (4.16 +/- 0.3 nmol/liter), P = 0.048] produced a significant reduction in total testosterone. Treatment with orlistat produced a 4.69% reduction in weight (99.0 +/- 6.0 vs. 94.6 +/- 6.1 kg, P = 0.002), and this reduction was more significant than the reduction produced by metformin (4.69 vs. 1.02%, P = 0.006). There was no significant reduction seen after either treatment group for fasting insulin, HOMA-IR, SHBG, or any of the lipid parameters studied.In this study, orlistat produced a significant reduction in weight and total testosterone. The reduction in total testosterone was similar to that seen after treatment with metformin. Therefore, orlistat may prove to be a useful adjunct in the treatment of PCOS.